Combination enzyme replacement and small molecule therapy...

Details Combination enzyme replacement and small molecule therapy... Combination enzyme replacement and small molecule therapy...

2011-03-22

2011-03-22

Chen, Shin-Lin (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S001000, C530S350000

Reexamination Certificate

active

07910545

ABSTRACT:
This invention provides various combinations of enzyme replacement therapy, gene therapy, and small molecule therapy for the treatment of lysosomal storage diseases.

REFERENCES:
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5549892 (1996-08-01), Friedman et al.
patent: 5650096 (1997-07-01), Harris et al.
patent: 5658567 (1997-08-01), Calhoun et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5719131 (1998-02-01), Harris et al.
patent: 5747471 (1998-05-01), Siegel et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5767099 (1998-06-01), Harris et al.
patent: 5783565 (1998-07-01), Lee et al.
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5836905 (1998-11-01), Lemelson et al.
patent: 5840702 (1998-11-01), Bedwell
patent: 5840710 (1998-11-01), Lee et al.
patent: 5851991 (1998-12-01), Lee et al.
patent: 5910487 (1999-06-01), Yew et al.
patent: 5912239 (1999-06-01), Siegel et al.
patent: 5916911 (1999-06-01), Shayman et al.
patent: 5925628 (1999-07-01), Lee et al.
patent: 5935936 (1999-08-01), Fasbender et al.
patent: 5939401 (1999-08-01), Marshall et al.
patent: 5942634 (1999-08-01), Siegel et al.
patent: 5945442 (1999-08-01), Shayman et al.
patent: 5948767 (1999-09-01), Scheule et al.
patent: 5948925 (1999-09-01), Keynes et al.
patent: 5952370 (1999-09-01), Shayman et al.
patent: 5968502 (1999-10-01), Treco et al.
patent: 6030995 (2000-02-01), Shayman et al.
patent: 6040332 (2000-03-01), Shayman et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6066626 (2000-05-01), Yew et al.
patent: 6465488 (2002-10-01), Butters et al.
patent: 6492332 (2002-12-01), Demopulos et al.
patent: 6495570 (2002-12-01), Jacob et al.
patent: 6610703 (2003-08-01), Jacob et al.
patent: 6660749 (2003-12-01), Butters et al.
patent: 6696059 (2004-02-01), Jacob et al.
patent: 7312324 (2007-12-01), Souza et al.
patent: 2001/0044453 (2001-11-01), Jacob et al.
patent: 2002/0127213 (2002-09-01), Jacob et al.
patent: 2002/0142985 (2002-10-01), Dwek et al.
patent: 2003/0017139 (2003-01-01), Souza et al.
patent: 2005/0075305 (2005-04-01), Dwek et al.
patent: 2006/0074107 (2006-04-01), Butters et al.
patent: 2007/0178081 (2007-08-01), Fan
patent: 1 171 128 (2003-06-01), None
patent: WO 97/09441 (1997-03-01), None
patent: WO 98/11206 (1998-03-01), None
patent: WO 99/41399 (1999-08-01), None
patent: WO 99/41400 (1999-08-01), None
patent: WO 99/57296 (1999-11-01), None
patent: WO 00/09153 (2000-02-01), None
patent: WO 00/62779 (2000-10-01), None
patent: WO 00/62780 (2000-10-01), None
patent: WO 01/97829 (2001-12-01), None
Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al., 2000, Trends in Biotech, vol. 18, p. 34-39.
Abe et al., Feb. 2000, Kidney International, vol. 57, pp. 446-454.
Bongiorno et al., 2003, JEADV, vol. 17, p. 676-679.
Masson et al., 2004, Joint Bone Spine, vol. 71, p. 381-383.
Wraith, J.E., 2006, J. of inherit. Metab. Dis., vol. 29, p. 442-447.
Eto et al., 2004, J. Inherit. Metab. Dis., vol. 27, p. 411-415.
Schiffmann et al., Jan. 2000, PNAS, vol. 97, No. 1, p. 365-370.
Abe et al., Jun. 1, 2000, The Journal of Clinical Investigation, vol. 105, No. 11, p. 1563-1571.
Smallwood et al., 2002, Virology, vol. 304, p. 135-145.
Chattopadhyay et al., 2004, Virus Research, vol. 99, p. 139-145.
Andersson et al., “N-Butyldeoxygalactonojirimycin: A More Selective Inhibitor of Glycosphingolipid Biosynthesis thanN-Butyldeoxynojirimycin, In Vitro and in Vivo,”Biochem. Pharmacol. 59:821-829 (2000).
Barbon et al., “AAV8-Mediated Hepatic Expression of Acid Sphingomyelinase Corrects the Metabolic Defect in the Visceral Organs of a Mouse Model of Niemann-Pick Disease,”Mol. Ther. 12(3):431-440 (2005).
Barton et al., “Replacement Therapy for Inherited Enzyme Deficiency—Macrophage-targeted Glucocerebrosidase for Gaucher's Disease,”N. Eng. J. Med. 324(21):1464-1470 (1991).
Beniaminovitz et al., “Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody,”N. Engl. J. Med. 342(9):613-619 (2000).
Berard et al., “A Review of Interleukin-2 receptor Antagonists in Solid Organ Transplantation,”Pharmacotherapy19(10):1127-1137 (1999).
Beutler et al., “Gaucher disease: Four families with Previously UndeMcribed mutations,”Proc. Assoc. Am. Physicians108(3):179-184 (1996).
Bielicki et al., “Advantages of Using Same Species Enzyme for Replacement Therapy in a Feline Model of Mucopolysaccharidosis Type VI,”J. Biol. Chem. 274(51):36335-36343 (1999).
Bodamer et al., “Dietary Treatment in Late-Onset Acid Maltase Deficiency,”Eur. J. Pediatr. 156(Suppl. 1):S39-S42 (1997).
Bou-Gharios et al., “Lysomal Storage Diseases: Mechanisms of Enzyme Replacement Therapy,”Histochem. J. 25(9):593-605 (1993).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1310 (1990).
Brady et al., “Enzyme Replacement Therapy in Fabry Disease,”J. Inherit. Metab. Dis., 24(Suppl. 2):18-24 (2001).
Branco et al., “Selective Deletion of Antigen-Specific, Activated T Cells by a Humanized mAb to CD2 (MEDI-507) is Mediated by NK Cells,”Transplantation68(10):1588-1596 (1999).
Branden et al.,Introduction to Protein Structure. 2d ed. Garland Publishing, Inc., New York: 1999; pp. 358-366.
Brooks, “Immune Response to Enzyme Rreplacement Therapy in Lysosomal Storage Disorder Patients and Animal Models,”Mol. Genet. Metabol. 68:268-275 (1999).
Buechner et al., “Central Nervous System Involvement in Anderson-Fabry Disease: A Clinical and MRI Retrospective Study,”J. Neurol. Neurosurg. Psychiatry79(11):1249-1254 (2008) (published online Jun. 5, 2008).
Byers et al., “Effect of Enzyme Replacement Therapy on Bone Formation in a Feline Model of Mucopolysaccharidosis Type VI,”Bone21(5):425-431 (1997).
Cabrera-Salazar et al., “Adeno-Associated Viral-Mediated Gene Therapy of Lysosomal Storage Disorders” inLysosomal Storage Disorders. Barranger and Cabrera-Salazar (Eds.) Springer Science+Business Media LLC: 2007; pp. 97-109.
Chen, “Glycogen Storage Diseases,”Harrison's Principles of Internal Medicine, Fauci et al (Eds.), pp. 2176-2182 (McGraw-Hill, 14thed., 1998).
Chirmule et al., “Readministration of Adenovirus Vector in Nonhuman Primate Lungs by Blockade of CD40-CD40 Ligand Interactions,”J. Virol. 74(7):3345-3352 (2000).
Cleary et al., “The Presenting Features of Mucopolysaccharidosis Type IH (Hurler Syndrome),”Acta. Paediatr. 84:337-339 (1995).
Colville et al., “Early Presentation in the Mucopolysaccharide Disorders,”Child: Care, Health and Development22(1):31-36 (1996).
Cox et al., “Novel Oral Treatment of Gaucher Disease withN-butyldeoxynojirimycin (OGT 918) to Decrease Substrate Biosynthesis,”Lancet355:1481-1485 (2000).
Crawley et al., “Enzyme Replacement Therapy in a Feline Model of Maroteaux-Lamy Syndrome,”J. Clin. Invest. 97(8):1864-1873 (1996).
Czartoryska et al., “Changes in Serum Chitotriosidase Activity with Cessation of Replacement Enzyme (Cerebrosidase) Administration in Gaucher Disease,”Clin. Biochem. 33(2):147-149 (2000).
Czartoryska et al., “Serum Chitotriosidase Activity in Gaucher Patients on Enzyme Replacement Therapy (ERT),”Clin. Biochem. 31(5):417-420 (1998).
Daniele et al., “Uptake of Recombinant Iduronate-2-Sulfatase Into Neuronal and Glial Cells in Vitro,”Biochim. Biophys. Acta1588:203-209 (2002).
Den Tandt et al., “Marked Increase of Methylumbelliferyl-Tetra-N-Acetylchitotetraoside Hydrolase Activity in Plasma from Gaucher Disease Patients,”J. Inherit. Metab. Dis. 19:344-350 (1996).
Desnick et al., “Enzyme Therapy in Fabry Disease: Differential in Vivo Plasma Clearance and Metaboli

Affiliated with

Also associated with

Rating

Combination enzyme replacement and small molecule therapy... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination enzyme replacement and small molecule therapy..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination enzyme replacement and small molecule therapy... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2728749